BIOR

Biora Therapeutics, Inc. · NASDAQ

Sector Health Services
Industry Medical/Nursing Services
Website bioratherapeutics.com
Employees(FY) 54
ISIN US74319F4046

Performance

-40.0%

-62.33%

-76.82%

-77.8%

-88.0%

YTD

-87.91%

Profile

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Advanced Technical Analysis

Technical Analysis of BIOR 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 43 suggesting a neutral stance, and a Technical Score of 26 reinforcing the bearish outlook. This combination points to a challenging environment for the stock, with potential for further declines.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of BIOR

Stock Rank

Recent News & Updates

2024-11-13 19:00
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results(Globenewswire)
2024-11-12 18:34
Biora Therapeutics Inc (BIOR) Q3 2024 Earnings Report Preview: What To Look For(Yahoo Finance)
2024-11-07 03:30
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update(Globenewswire)
2024-10-28 20:00
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2024-10-27 20:00
Biora Therapeutics Shares Progress on Smaller BioJet Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting(Globenewswire)
2024-10-13 20:00
Biora Therapeutics to Reveal 00-Size BioJet Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting(Globenewswire)
2024-10-06 20:00
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium(Globenewswire)
2024-09-29 20:00
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024(Globenewswire)
2024-09-08 20:00
Biora Therapeutics Achieves ISO 13485 Certification(Globenewswire)
2024-08-27 20:00
Biora Therapeutics Announces Positive Nasdaq Listing Decision(Globenewswire)
2024-08-25 20:00
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-13 02:01
Q2 2024 Biora Therapeutics Inc Earnings Call(Yahoo Finance)
2024-08-12 04:15
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results(Globenewswire)
2024-08-12 04:05
Biora Therapeutics Announces Funding Agreement with Existing Investors(Globenewswire)
2024-08-08 04:30
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update(Globenewswire)
2024-08-05 20:00
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference(Globenewswire)
2024-07-17 20:00
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event(Globenewswire)
2024-07-07 20:00
Biora Therapeutics to Host Virtual KOL Event on NaviCap Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024(Globenewswire)
2024-06-30 20:00
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600(Globenewswire)
2024-06-10 20:00
Biora Therapeutics Announces Presentation on the BioJet Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024(Globenewswire)
2024-05-19 20:00
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap Platform at Digestive Disease Week 2024(Globenewswire)
2024-05-15 15:08
Biora Therapeutics Inc (BIOR) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ...(Yahoo Finance)
2024-05-15 08:53
BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-15 04:05
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results(Globenewswire)
2024-05-06 20:00
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update(Globenewswire)
2024-05-05 20:00
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap Oral Delivery Platform at Digestive Disease Week 2024(Globenewswire)
2024-04-29 20:00
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600(Globenewswire)
2024-04-07 20:00
Biora Therapeutics Announces New Patent Covering its BioJet Liquid Jet Delivery Technology(Globenewswire)
2024-04-03 20:00
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development(Globenewswire)
2024-04-03 04:05
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.